These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 38288121)

  • 1. Role of interferons in the antiviral battle: from virus-host crosstalk to prophylactic and therapeutic potential in SARS-CoV-2 infection.
    Mihaescu G; Chifiriuc MC; Filip R; Bleotu C; Ditu LM; Constantin M; Cristian RE; Grigore R; Bertesteanu SV; Bertesteanu G; Vrancianu CO
    Front Immunol; 2023; 14():1273604. PubMed ID: 38288121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?
    Sacchi A; Giannessi F; Sabatini A; Percario ZA; Affabris E
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon antagonists encoded by SARS-CoV-2 at a glance.
    Lee JH; Koepke L; Kirchhoff F; Sparrer KMJ
    Med Microbiol Immunol; 2023 Apr; 212(2):125-131. PubMed ID: 35366686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type I IFNs: A Blessing in Disguise or Partner in Crime in MERS-CoV-, SARS-CoV-, and SARS-CoV-2-Induced Pathology and Potential Use of Type I IFNs in Synergism with IFN-
    Anjum FR; Anam S; Abbas G; Mahmood MS; Rahman SU; Goraya MU; Abdullah RM; Luqman M; Ali A; Akram MK; Chaudhry TH
    Viral Immunol; 2021 Jun; 34(5):321-329. PubMed ID: 33181057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of impairment of interferon production by SARS-CoV-2.
    Hoang HD; Naeli P; Alain T; Jafarnejad SM
    Biochem Soc Trans; 2023 Jun; 51(3):1047-1056. PubMed ID: 37199495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.
    Khalil AM; Nogales A; Martínez-Sobrido L; Mostafa A
    Front Cell Infect Microbiol; 2024; 14():1357866. PubMed ID: 38375361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased Sensitivity of SARS-CoV-2 to Type III Interferon in Human Intestinal Epithelial Cells.
    Metz-Zumaran C; Kee C; Doldan P; Guo C; Stanifer ML; Boulant S
    J Virol; 2022 Apr; 96(7):e0170521. PubMed ID: 35262371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.
    Zhang J; Zhao C; Zhao W
    Front Immunol; 2021; 12():633769. PubMed ID: 33912161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons.
    Jafarzadeh A; Nemati M; Saha B; Bansode YD; Jafarzadeh S
    Viral Immunol; 2021 Jun; 34(5):307-320. PubMed ID: 33147113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Myeloid Differentiation Primary Response Protein 88 (MyD88) and Galectin-3 to Develop Broad-Spectrum Host-Mediated Therapeutics against SARS-CoV-2.
    Saikh KU; Anam K; Sultana H; Ahmed R; Kumar S; Srinivasan S; Ahmed H
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
    Park A; Iwasaki A
    Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.
    Znaidia M; Demeret C; van der Werf S; Komarova AV
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulated Interferon Response and Immune Hyperactivation in Severe COVID-19: Targeting STATs as a Novel Therapeutic Strategy.
    Eskandarian Boroujeni M; Sekrecka A; Antonczyk A; Hassani S; Sekrecki M; Nowicka H; Lopacinska N; Olya A; Kluzek K; Wesoly J; Bluyssen HAR
    Front Immunol; 2022; 13():888897. PubMed ID: 35663932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.
    Vanderheiden A; Ralfs P; Chirkova T; Upadhyay AA; Zimmerman MG; Bedoya S; Aoued H; Tharp GM; Pellegrini KL; Manfredi C; Sorscher E; Mainou B; Lobby JL; Kohlmeier JE; Lowen AC; Shi PY; Menachery VD; Anderson LJ; Grakoui A; Bosinger SE; Suthar MS
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32699094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 NSP7 inhibits type I and III IFN production by targeting the RIG-I/MDA5, TRIF, and STING signaling pathways.
    Deng J; Zheng Y; Zheng SN; Nan ML; Han L; Zhang J; Jin Y; Pan JA; Gao C; Wang PH
    J Med Virol; 2023 Mar; 95(3):e28561. PubMed ID: 36755358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of Type I and III Interferons in COVID-19.
    Choi H; Shin EC
    Yonsei Med J; 2021 May; 62(5):381-390. PubMed ID: 33908208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on Innate Immune Responses during SARS-CoV-2 Infection.
    Zhang Y; Chen S; Jin Y; Ji W; Zhang W; Duan G
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I and III interferon responses in SARS-CoV-2 infection.
    Kim YM; Shin EC
    Exp Mol Med; 2021 May; 53(5):750-760. PubMed ID: 33953323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The battle between host and SARS-CoV-2: Innate immunity and viral evasion strategies.
    Zhang S; Wang L; Cheng G
    Mol Ther; 2022 May; 30(5):1869-1884. PubMed ID: 35176485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.